In recent years, the global scenario of HIV infection has dramatically changed with the widespread implementation of antiretroviral treatment (ART) and the aim to reach the goals of the UNAIDS initiative "90-90-90: Treatment for all" (www.unaids.org/en/resources/909090) by 2030. Furthermore, ground-breaking scientific evidence has revolutionized the life of people living with HIV/AIDS (PLWH). Undetectable equals untransmittable (U=U) is one of the most important messages since the rise of HIV epidemic with the power to reduce the stigma related to infectiveness [1] . Among the potential strategies to be implemented to end HIV epidemics, treatment as prevention is the one with the strong scientific evidence [2] .
In their work Zhu J et al have formalized a model assessing the potential impact of integrase strand-transfer inhibitor (INSTI)-containing regimens in reducing onward HIV transmissions in British Columbia [3] . By applying two previously described models of HIV transmission [4, 5] , which are based on HIV-RNA viral load and the natural history of HIV infection (early vs chronic vs late), the authors demonstrated how the use of INSTI-based regimens in naïve patients could potentially reduce the risk of HIV transmission when compared to non INSTI-based regimens in their cohort. In particular, a HIV transmission risk reduction of 25%, according to the model by Fraser C et al, has been estimated for gay, bisexual and other men who have sex with men (gbMSM) starting an INSTI-based regimen with a viral load ≥ 5log 10 copies/mL irrespectively of HIV stage [5] . Authors concluded that INSTI-based regimens have the potential to avert onward HIV transmission by achieving a fast virologic suppression, in particular among gbMSM with pretreatment high viral load.
Although these data are sound, some potential pitfalls should be acknowledged to correctly interpret the findings reported by Zhu J et al. [6] . In other words, the findings of the authors should be considered as confirmatory and add a strong scientific evidence to a change in the prescribing behaviour occurring in everyday clinical practice. Moreover, the study relies on the assumption that there are no changes in the behaviours of a newly infected PLWH. However, it could not be excluded that changes in the sexual behaviours after the diagnosis -due to extensive counselling and a novel risk perception -could impact on the risk of HIV transmission [7] . The authors focus their attention on a high-risk gbMSM population who show the highest number of previous condomless sexual intercourses. In this population, the use of INSTIs is advisable not only to reduce HIV risk by dropping the time of HIV-RNA detectability (defined as HIV-RNA N200 cp/mL), but also by reducing the risk of potential drugdrug interaction with chem-sex compounds [8] . The burden of drugs resistance to antiretrovirals is still the main cause of virologic failure, at least in developed countries. The impact of INSTI drug resistance within the first-line treatment is still very limited [9] , thus this pharmacological class is potentially useful in all HIV-1-infected individuals who start their first ART.
When we think about the potential window of HIV transmission opportunities after the engagement in care of PLWH, it's important to consider the timespan between HIV diagnosis and ART initiation. In fact, the potential advantage of HIV-RNA rapid reduction obtained with INSTIbased regimens should be considered additive to the "same day strategy" which is potentially practicable with high genetic barrier INSTIs, such as dolutegravir and bictegravir. The "same day strategy" has been demonstrated to increase the linkage to care of PLWH by reducing the stigma and the fear related to the infectiveness [10] .
Ending HIV epidemic is an ambitious goal and no single intervention by itself is able to interrupt the transmission chain. Conversely, a multilevel intervention strategy relying on prevention strategies (i. 
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